Treatment of hepatocellular carcinoma with autologous platelets encapsulating sorafenib or lenvatinib: a novel therapy exploiting tumor‐platelet interactions

2021 ◽  
Author(s):  
Hiroki Tanaka ◽  
Kie Horioka ◽  
Takumu Hasebe ◽  
Koji Sawada ◽  
Shunsuke Nakajima ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Novel Therapy

scholarly journals miR-34a Inhibits Cell Proliferation by Targeting SATB2 in Hepatocellular Carcinoma

2018 ◽  
Vol 2018 ◽  
pp. 1-7 ◽  
Author(s):  
Gang Wu ◽  
Zhixi Li ◽  
Youyu Wang ◽  
Xueming Ju ◽  
Rui Huang
Keyword(s):  
Hepatocellular Carcinoma ◽  
Cell Proliferation ◽  
Hepg2 Cells ◽  
Hepatoma Cell ◽  
Luciferase Reporter ◽  
Hepatoma Cell Line ◽  
Novel Therapy ◽  
The Third ◽  
Direct Target

Hepatocellular carcinoma (HCC) is the most common type of malignancy of the liver and has been reported as the third most frequent cause of cancer associated death worldwide. Accumulating evidence showed that the expression of miR-34a was abnormal in HCC patients; however, the role of miR-34a in HCC is not clear. In this study, we have observed low expression of the miR-34a in both HCC tissues and hepatoma cell line as compared to normal control. Further to investigate the role of miR-34a in HCC development, HepG2 cells were transfected with miR-34a mimic. Following transfection, miR-34a expression was significantly increased, which further repressed proliferation of HepG2 cells. Bioinformatics, Luciferase Reporter, RT-qPCR, and western blotting assays indicated that special AT-rich sequence-binding protein-2 (SATB2) is a direct target of miR-34a in HCC cells. There was a negative correlation between the expression levels of SATB2 and miR-34a. Investigation into the molecular mechanism indicated that miR-34a regulated cell proliferation through inhibiting SATB2. Therefore, the results of the present study may improve understanding regarding the role of miR-34a in regulating cell proliferation and contribute to the development of novel therapy of HCC.

scholarly journals Going with the gut: probiotics as a novel therapy for hepatocellular carcinoma

2019 ◽  
Vol 8 (3) ◽  
pp. 295-297
Author(s):  
Alberto Nicoletti ◽  
Maurizio Pompili ◽  
Antonio Gasbarrini ◽  
Francesca R. Ponziani
Keyword(s):  
Hepatocellular Carcinoma ◽  
Novel Therapy

scholarly journals Optimal application of stereotactic body radiotherapy and radiofrequency ablation treatment for different multifocal hepatocellular carcinoma lesions in patients with Barcelona Clinic Liver Cancer stage A4–B1: a pilot study

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Feiqian Wang ◽  
Kazushi Numata ◽  
Atsuya Takeda ◽  
Katsuaki Ogushi ◽  
Hiroyuki Fukuda ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Clinical Practice ◽  
Radiofrequency Ablation ◽  
Liver Cancer ◽  
Stereotactic Body Radiotherapy ◽  
Large Scale ◽  
White Blood Cells ◽  
Novel Therapy ◽  
One Year ◽  
The One

Abstract Background In clinical practice, many hepatocellular carcinoma (HCC) patients in Barcelona Clinical Liver Cancer (BCLC) stage A4–B1 cannot receive the curative treatments of liver transplantation, resection, and radiofrequency ablation (RFA), which are the recommended options according to liver cancer guidelines. Our aim is to study the feasibility of RFA and stereotactic body radiotherapy (SBRT) as a curative treatment for different multifocal HCCs in BCLC stage A4–B1 patients. Methods From September 2014 to August 2019, 39 multifocal HCC lesions (median diameter: 16.6 mm) from 15 patients (median age: 73 years) were retrospectively selected. Among them, 23 were treated by RFA and the other 16 by SBRT because of predictable insufficiency and/or risk related to RFA performance. The indicators for evaluating this novel therapy were the tumor response, prognosis (recurrence and survival), and adverse effects (deterioration of laboratory test values and severe complications). Results The median follow-up duration was 31.3 months (range: 15.1–71.9 months). The total patients with a one-year complete response, stable disease, or disease progression were 11, 1, and 3, respectively. In total, 8 and 2 patients had confronted intrahepatic or local recurrence, respectively. The one-year progression-free survival rate and local control rate were 80% (12/15 patients) and 97.4% (38/39 lesions), respectively. The median time to progression was 20.1 (2.8–45.1) months. The one- and two-year survival rates were 100 and 88.9%, respectively. In up to five months’ observation, no patient showed severe complications. Seven, four, and two patients had slight changes in their white blood cells, platelet count, or albumin–bilirubin grade, respectively. Conclusions For patients with BCLC stage A4–B1, RFA and SBRT treatment for different multifocal HCCs may be a potential option because of the favorable prognosis and safety. However, before its application in clinical practice, prospective, controlled, large-scale studies are needed to further confirm our conclusions.

scholarly journals Effect of Diphtheria Toxin-Based Gene Therapy for Hepatocellular Carcinoma

Cancers ◽  
2020 ◽  
Vol 12 (2) ◽  
pp. 472 ◽  
Author(s):  
Kenya Kamimura ◽  
Takeshi Yokoo ◽  
Hiroyuki Abe ◽  
Norihiro Sakai ◽  
Takuro Nagoya ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Gene Therapy ◽  
Cell Growth ◽  
Gene Delivery ◽  
Diphtheria Toxin ◽  
Mice Model ◽  
Novel Therapy ◽  
Liver Cancers ◽  
Afp Promoter

Hepatocellular carcinoma (HCC) is a major global malignancy, responsible for >90% of primary liver cancers. Currently available therapeutic options have poor performances due to the highly heterogeneous nature of the tumor cells; recurrence is highly probable, and some patients develop resistances to the therapies. Accordingly, the development of a novel therapy is essential. We assessed gene therapy for HCC using a diphtheria toxin fragment A (DTA) gene-expressing plasmid, utilizing a non-viral hydrodynamics-based procedure. The antitumor effect of DTA expression in HCC cell lines (and alpha-fetoprotein (AFP) promoter selectivity) is assessed in vitro by examining HCC cell growth. Moreover, the effect and safety of the AFP promoter-selective DTA expression was examined in vivo using an HCC mice model established by the hydrodynamic gene delivery of the yes-associated protein (YAP)-expressing plasmid. The protein synthesis in DTA transfected cells is inhibited by the disappearance of tdTomato and GFP expression co-transfected upon the delivery of the DTA plasmid; the HCC cell growth is inhibited by the expression of DTA in HCC cells in an AFP promoter-selective manner. A significant inhibition of HCC occurrence and the suppression of the tumor marker of AFP and des-gamma-carboxy prothrombin can be seen in mice groups treated with hydrodynamic gene delivery of DTA, both 0 and 2 months after the YAP gene delivery. These results suggest that DTA gene therapy is effective for HCC.

1107 Novel Therapy for Hepatocellular Carcinoma: Immunotherapy

2019 ◽  
Vol 114 (1) ◽  
pp. S624-S624
Author(s):  
Patricia D. Jones ◽  
Kristin Gmunder ◽  
Jeremy McLaughlin ◽  
Paul M. Martin ◽  
Cristina Herrera ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Novel Therapy

Multimodality treatment of hepatocellular carcinoma

1998 ◽  
Vol 13 (11-s4) ◽  
pp. S315-S319 ◽  
Author(s):  
ZHAO-YOU TANG ◽  
XIN-DA ZHOU ◽  
ZENG-CHEN MA ◽  
ZHI-QUAN WU ◽  
JIA FAN ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Multimodality Treatment
Sign in / Sign up

Export Citation Format

Share Document